Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Tony Keating
CEO & Managing Director, Tony Keating
Source: TechInvest Magazine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthcare company ResApp Health (RAP) is helping fight the COVID-19 pandemic with a smartphone app
  • The app, called ResAppDX-EU, is able to diagnose severe respiratory conditions through a phone’s microphone
  • A patient simply coughs into their phone and the ResApp tech does the rest
  • The app has been licenced to a Brisbane COVID-19 relief clinic for free to help ease the burden of the pandemic on hospitals
  • Shares in ResApp are trading almost 10 per cent higher today, currently worth 18 cents each

Healthcare company ResApp Health (RAP) is helping fight the COVID-19 pandemic with its respiratory diagnostic smartphone app.

The app, called ResAppDX-EU, is able to diagnose and measure the severity of respiratory conditions through nothing but a mobile phone. A patient simply coughs into their device’s microphone and ReApp’s algorithms do the rest.

The product is approved for use in Europe through CE Mark certification and has Therapeutic Goods Administration (TGA) approval in Australia.

Now, the mobile app is being used to assist healthcare workers fighting COVID-19.

Pressure relief

ResApp’s mobile diagnostic app has been tested at a government-funded COVID-19 clinic in Brisbane over the past month.

The clinic is designed to ease the burden on the healthcare system by treating mild-to-moderate respiratory systems that can be associated with the coronavirus. The clinic has also been testing patients for COVID-19.

Today, ResApp told shareholders it has given the clinic a licence to use the ResAppDx-EU app for free until the start of September 2020.

The app will help identify patients with lower respiratory tract infections, pneumonia, asthma, and more.

Dr Evan Jones, Director of Health Hub Doctors Morayfield and Associate Professor of the University of Sunshine, said respiratory illness are the most common conditions the clinic sees but often may have nothing to do with COVID-19.

“Our doctors have found ResAppDx-EU invaluable in helping them make differential diagnoses of respiratory disease,” Dr Evan said.

“Being a non-contact diagnostic aid, ResAppDx-EU is especially useful when assessing patients in the difficult conditions associated with managing possible COVID-19 cases,” he said.

ResApp CEO and Managing Director Tony Keating said the company’s goal is to make diagnostic testing as easy and accurate as possible in the tough conditions currently being faced by doctors.

“We are pleased to provide Health Hub Doctors Morayfield with a no-cost licence to assist during the COVID-19 pandemic and generate further real-world evidence of how ResAppDx-EU enhances the diagnosis and treatment of patients presenting with respiratory systems,” he said.

Of course, with no fees being paid for the licence, today’s news is unlikely to change ResApp’s bank statement. However, the adoption of the ResApp tech for such an important issue is a vote of confidence for the company’s app and bodes well for future uptake of the device.

Shares in ResApp are trading 9.38 per cent higher today, currently worth 18 cents each.

RAP by the numbers
More From The Market Herald
Amplia Therapeutics - CEO and MD, John Lambert

" Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan.
Creso Pharma (ASX:CPH) - Creso Pharma

" Creso Pharma’s (ASX:CPH) Halucenex secures Dealer’s Licence amendment

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence.

" Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) granted ethics approval for chronic pain trial

Zelira Therapeutics (ZLD) has received ethics approval for its Phase 2a clinical trial for chronic pain.